Affymetrix Launches Program to Advance Cancer Research
Partnership With Leading Scientists Aims to Accelerate Breakthroughs in More Than 10 Types of Cancers
Affymetrix Inc. announced the launch of the collaborations in Cancer Research Program, an alliance between Affymetrix and up to 30 leading European cancer researchers. As part of the program, Affymetrix will partially fund selected research projects that demonstrate clinical utility, enabling participants to develop new approaches to elucidate cancer mechanisms and to accelerate discoveries in more than 10 different forms of cancer.
The studies selected for the Collaborations in Cancer Research Program incorporate a number of different microarray-based applications, including copy number analysis, chromatin immunoprecipitation (ChIP), gene expression and splicing pattern analysis. In addition to helping participants obtain tools and training, Affymetrix will also provide forums where investigators can exchange knowledge and share best practices.
Participants in the Collaborations in Cancer Research Program were selected on the basis of past contributions to their respective fields, and the potential to make significant advancements in their current research.
Later this year, Affymetrix will expand the Collaborations in Cancer Research Program to selected groups in North America and Japan.
Other news from the department business & finance
